Peptide Cycling and Blood Work: What Lifters Test Before and During a Cycle

The 'Run It 'Til It Works' Crowd is Playing with Fire

Lifters who plan anabolic steroid cycles down to the milligram, with post-cycle therapy (PCT) mapped out before the first injection, often treat peptides much more loosely. The plan usually sounds something like, "I'll run it 'til my wallet's empty or my shoulder feels better."

That's a mistake. Peptides are not harmless supplements. They are signaling molecules that interact with receptors all over your body. Running growth hormone secretagogues like CJC-1295 or ipamorelin isn't like taking extra creatine. You're acting directly on the growth hormone (GH) / IGF-1 axis, and in human trials of GH-raising compounds that shows up as reduced insulin sensitivity, water retention, and nerve symptoms such as carpal tunnel syndrome.

The usual reason for cycling is giving receptors a break to prevent downregulation, and there's some human evidence for it: in a 16-week hexarelin study, the GH response dropped partway and came back after 4 weeks off. Cycling is also about managing the systemic effects. And you can't manage what you don't measure. Blood work is the most objective scorecard you have.

Your Pre-Cycle Blueprint: The Non-Negotiable Baseline

Your baseline blood work is the map. It's the 'you' under normal conditions, the set point you're aiming to return to after your cycle.

Here's what users check and, more importantly, why.

• The GH/IGF-1 axis: IGF-1 (insulin-like growth factor 1) is the main marker. A single fasting growth hormone reading isn't very useful, because GH is released in pulses and one draw can land on a peak or a trough. IGF-1 reference ranges fall with age, so the same number means different things at 25 and at 50. Someone starting at 150 ng/mL has more room below the top of their range than someone starting at 280 ng/mL.
• Metabolic panel: Fasting glucose and HbA1c. Reduced insulin sensitivity is the best-documented side effect of GH-raising compounds. The CDC puts prediabetes at a fasting glucose of 100-125 mg/dL or an HbA1c of 5.7-6.4%, so anyone already in or near those ranges starts with less margin. The tesamorelin label tells prescribers to check glucose before and during treatment.
• Hormonal health: Total and free testosterone, estradiol (sensitive assay) and prolactin. In a small human study, single doses of GHRP-2 and hexarelin raised prolactin, ACTH and cortisol. A baseline prolactin makes a later reading possible to interpret, and high prolactin can lower libido.
• General health markers: A complete blood count (CBC) and comprehensive metabolic panel (CMP) will check your kidney function, liver enzymes, and red/white blood cells. It's just good practice.

Users commonly get this done 1-2 weeks before a planned start date. This data is your anchor. Every later decision gets referenced against these numbers.

Mid-Cycle Checkpoints: Reading the Objective Signs

How you feel on cycle is important, but it's subjective. Scale weight, joint relief and sleep quality are all useful feedback. But they don't tell you if your fasting glucose has quietly climbed by 15 points or if your IGF-1 is pushing past the top of its reference range.

For a typical 8-12 week cycle, users commonly describe a mid-cycle test around week 4-6. That timing is community practice, not something a study has tested, but it allows you to catch negative trends early.

What to check depends on the compound. The triggers in the last column are ones users commonly cite, not cutoffs from trials, and IGF-1 ranges vary by age and lab.

No single 'bad' number decides it. What matters is the trend. If your numbers are holding steady or moving in a controlled way, users generally carry on. If they're heading in the wrong direction, it's time to act.

The Art of the Pivot: Using Data to Steer the Ship

So your mid-cycle labs came back and something's off. This is where monitoring pays for itself. Instead of panicking or quitting, you can make an educated change. The scenarios below describe what users report doing; none of these adjustments has been tested in a trial.

Scenario 1: Pre-diabetic Glucose Levels

You're 5 weeks into a tesamorelin cycle for fat loss. You feel great, but your fasting glucose jumped from a baseline of 89 to 104 mg/dL. That's in the CDC's prediabetes range, and the tesamorelin label lists glucose intolerance and diabetes among its warnings. (Tesamorelin is a prescription medicine approved only to reduce abdominal fat in adults with HIV lipodystrophy, and its label says it isn't indicated for weight loss.)

• The bad move: Ignoring it and hoping it goes away.
• What users report doing: Common community responses are cutting the dose by 25-50%, tightening carbohydrate timing around workouts, and retesting in 2-3 weeks. Some add berberine, often around 500 mg before carb-heavy meals; that's a forum practice, and we found no study of berberine alongside GH secretagogues. If glucose doesn't come back down, users end the cycle. A fasting glucose in the prediabetes range is also worth taking to a doctor.

Scenario 2: Sky-High IGF-1

You're running a modest 100 mcg of ipamorelin and CJC-1295 (in forum use, usually the no-DAC form, Mod GRF 1-29) twice a day. You feel good, but your IGF-1 came back at 450 ng/mL. Your baseline was 200.

• The bad move: Thinking 'more is better' and pushing for even higher numbers.
• What users report doing: Treating it as a high response and lowering the dose, often to 50-75 mcg per injection, then retesting to see whether IGF-1 settles back toward the upper part of the reference range. The concern is that nobody knows what years of raised IGF-1 do; the tesamorelin label says the effects of prolonged IGF-1 elevation are unknown. No study has measured how much benefit survives a lower dose, so forum claims such as "90% of the benefit" have nothing behind them.

Scenario 3: Prolactin Problems on GHRP-2

You decided to use the older, cheaper GHRP-2 to save a few bucks. Four weeks in, your libido is tanking and you feel strangely lethargic. Your blood work confirms it: prolactin is double the top of the reference range.

• The bad move: Pushing through and feeling miserable.
• What users report doing: Forum posts describe two options. One is adding P-5-P (pyridoxal 5'-phosphate, the active form of vitamin B6), often at 100-200 mg/day. P-5-P isn't a dopamine agonist, though. It's a coenzyme the body uses to make neurotransmitters, and we found no trial showing it lowers prolactin raised by GHRP-2. Those amounts also sit at or above the US upper limit for adults of 100 mg/day (the European Food Safety Authority set 12 mg/day in 2023), and long-term high-dose B6 has been linked to nerve damage. The more common move is dropping GHRP-2 for ipamorelin. In swine, ipamorelin didn't raise ACTH or cortisol even at doses far above those needed for GH release, while GHRP-2 and GHRP-6 did; human data on ipamorelin and prolactin are limited. A prolactin reading at twice the upper limit is worth taking to a doctor either way.

What we still don't know

As of October 2026, no controlled human study has tested a peptide cycling schedule or a lab-monitoring interval. The on/off patterns and thresholds above come from users and vendors.

The human data on tolerance is thin and mixed. Daily GHRP-2 injections in nine young men gave a smaller GH response by day 5 and no rise in IGF-1. Twice-daily hexarelin in 12 older adults lost part of its effect by week 4, and the response came back after 4 weeks off. Yet the MK-677 trial data show GH and IGF-1 staying raised over 2 years, so loss of effect isn't universal across the class. Nobody has studied whether breaks restore the response to ipamorelin or CJC-1295.

For a marker-by-marker breakdown, see the baseline and on-cycle lab test guide, and for monitoring over years rather than weeks, the long-term peptide monitoring article.